EpiFrontier Therapeutics

EpiFrontier is a Japanese clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics that target epigenetic regulators. The company's primary expertise lies in modulating epigenetic enzymes to treat various forms of cancer, with a specific emphasis on Lysine-specific demethylase 1 (LSD1). Its lead program, EF-001, is currently undergoing clinical evaluation for hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndromes. By leveraging a proprietary drug discovery platform and academic research from the University of Tokyo, EpiFrontier aims to develop precision medicines that can overcome therapeutic resistance. The company is headquartered in Tokyo and is supported by a network of prominent Japanese venture capital investors.